The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
about
K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Exosomes genetic cargo in lung cancer: a truly Pandora's boxTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKPrognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.Liquid biopsy: monitoring cancer-genetics in the blood.Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasKRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review.The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer.Targeted therapy for NSCLC with driver mutations.Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value.The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.Circulating cell-free DNA: a potential biomarker in lung cancer
P2860
Q26829425-EDF14CA4-D4C5-426A-A709-C282BB88502BQ28077340-03AC0A62-6372-486A-80F7-B97FE429118AQ28079149-EA6B3090-45DC-413F-90AE-8B3B9A550989Q28083446-318DB08F-7E26-4618-BFB0-4D462581FF49Q33779727-A9DCE1CA-6728-4B89-9140-3544E0ED7AA8Q33829668-76C9AE18-661E-467F-8DE9-6F5D3F9F9992Q34356149-BA12AB68-487A-4955-8FC2-2BE5A5ECFA24Q35775729-A1A4E202-F5B4-4D0C-AC2A-86C685ECD7BEQ36102524-CF4F8FBE-E6D5-4C02-AD5A-04BBC5A93582Q36906563-8CB1D12A-62B7-47A3-ADD8-A3DD8827428AQ36946809-EDD0E6C0-ECE4-4457-8BD1-D8AFF918DFD1Q37536958-5ECB2BB9-D817-4ED3-83A8-3A5FE1788E70Q37619675-2538026D-3CA6-4204-BBD1-0F0AB5BAD1F5Q38019976-2C9C6EED-4500-41D4-9434-134045C8AC73Q38127728-87166963-3191-42A1-8A44-D42E2D127857Q38263419-5E68CD75-4BBD-40B9-BFBD-6CFF609E4F8FQ39106800-6A10B493-1367-4E9D-AB68-5445683AE1ABQ39142265-27CDF2B8-C1EC-488C-A2B3-676F777FF518Q41347645-39FFE30B-1575-47BA-AF89-9F9791F63155Q41347759-2B414D51-27FC-415A-88BB-DB2422BBCCC4Q44658636-82E602CA-B1D7-4225-9E4E-24CD32EFF50BQ53165144-8994D85B-D42B-428C-A1D7-79432CAF74A1Q57306273-9B024D57-36DC-4766-8E60-D233A927E6ED
P2860
The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The identification of KRAS mut ...... all cell lung cancer patients.
@en
The identification of KRAS mut ...... all cell lung cancer patients.
@nl
type
label
The identification of KRAS mut ...... all cell lung cancer patients.
@en
The identification of KRAS mut ...... all cell lung cancer patients.
@nl
prefLabel
The identification of KRAS mut ...... all cell lung cancer patients.
@en
The identification of KRAS mut ...... all cell lung cancer patients.
@nl
P2093
P50
P1433
P1476
The identification of KRAS mut ...... mall cell lung cancer patients
@en
P2093
Ana Blasco
Cristina Caballero
Nieves del Pozo
Rafael Rosell
Ricardo Guijarro
Sandra Gallach
P304
P356
10.1016/J.LUNGCAN.2010.09.005
P577
2010-11-12T00:00:00Z